APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cancer Immunotherapy Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Cancer Immunotherapy Drug Industry Growth and Trends Forecast to 2032

20 December 2025116 pages

Choose your research edition.

Industry ResearchCancer Immunotherapy Drug Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Immunotherapy Drug Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal Cancer Immunotherapy Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Immunotherapy Drug Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Immunotherapy Drug Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Cancer Immunotherapy Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Cancer Immunotherapy Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Cancer Immunotherapy Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cancer Immunotherapy Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Cancer Immunotherapy Drug include Novartis AG, Merck & Co., Inc., Jiangsu Hengrui Medicine Corporation, Pfizer, Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Roche Holding AG, Medimmune, LLC and Juno Pharmaceuticals Pty Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Cancer Immunotherapy Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Cancer Immunotherapy Drug market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Cancer Immunotherapy Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Cancer Immunotherapy Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Cancer Immunotherapy Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Cancer Immunotherapy Drug Market by Company

Novartis AG

Merck & Co., Inc.

Jiangsu Hengrui Medicine Corporation

Pfizer, Inc.

Bristol-Myers Squibb Company

AstraZeneca plc

Roche Holding AG

Medimmune, LLC

Juno Pharmaceuticals Pty Ltd.

Incyte Corporation

Gilead Sciences, Inc. (Kite Pharma)

Celgene Corporation

bluebird bio, Inc.

BeiGene

Autolus Therapeutics plc

Cancer Immunotherapy Drug Segment by Type

T-Cell Stimulant

PDL-1 Inhibitor

PD-1 Inhibitor

CTLA Antibody

Cancer Immunotherapy Drug Segment by Application

Hospital

Clinic

Others

Cancer Immunotherapy Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Immunotherapy Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Immunotherapy Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Immunotherapy Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Cancer Immunotherapy Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Cancer Immunotherapy Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of T-Cell Stimulant Table 2. Major Company of PDL-1 Inhibitor Table 3. Major Company of PD-1 Inhibitor Table 4. Major Company of CTLA Antibody Table 5. Global Cancer Immunotherapy Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Cancer Immunotherapy Drug Sales by Type (2021-2026) & (k units) Table 7. Global Cancer Immunotherapy Drug Sales Market Share in Volume by Type (2021-2026) Table 8. Global Cancer Immunotherapy Drug Sales by Type (2021-2026) & (US$ Million) Table 9. Global Cancer Immunotherapy Drug Sales Market Share in Value by Type (2021-2026) Table 10. Global Cancer Immunotherapy Drug Price by Type (2021-2026) & (US$/unit) Table 11. Global Cancer Immunotherapy Drug Sales by Type (2027-2032) & (k units) Table 12. Global Cancer Immunotherapy Drug Sales Market Share in Volume by Type (2027-2032) Table 13. Global Cancer Immunotherapy Drug Sales by Type (2027-2032) & (US$ Million) Table 14. Global Cancer Immunotherapy Drug Sales Market Share in Value by Type (2027-2032) Table 15. Global Cancer Immunotherapy Drug Price by Type (2027-2032) & (US$/unit) Table 16. North America Cancer Immunotherapy Drug Sales by Type (2021-2026) & (k units) Table 17. North America Cancer Immunotherapy Drug Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Cancer Immunotherapy Drug Sales by Type (2021-2026) & (k units) Table 19. Europe Cancer Immunotherapy Drug Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Cancer Immunotherapy Drug Sales by Type (2021-2026) & (k units) Table 21. Asia-Pacific Cancer Immunotherapy Drug Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Cancer Immunotherapy Drug Sales by Type (2021-2026) & (k units) Table 23. Latin America Cancer Immunotherapy Drug Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Cancer Immunotherapy Drug Sales by Type (2021-2026) & (k units) Table 25. Middle East and Africa Cancer Immunotherapy Drug Sales by Type (2021-2026) & (US$ Million) Table 26. Cancer Immunotherapy Drug Industry Trends Table 27. Cancer Immunotherapy Drug Industry Drivers Table 28. Cancer Immunotherapy Drug Industry Opportunities and Challenges Table 29. Cancer Immunotherapy Drug Industry Restraints Table 30. Global Cancer Immunotherapy Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Cancer Immunotherapy Drug Revenue Market Share by Company (2021-2026) Table 32. Global Cancer Immunotherapy Drug Sales by Company (2021-2026) & (k units) Table 33. Global Cancer Immunotherapy Drug Sales Share by Company (2021-2026) Table 34. Global Cancer Immunotherapy Drug Market Price by Company (2021-2026) & (US$/unit) Table 35. Global Cancer Immunotherapy Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Cancer Immunotherapy Drug Major Company Production Sites and Headquarters Table 37. Global Cancer Immunotherapy Drug Company, Product Type & Application Table 38. Global Cancer Immunotherapy Drug Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Cancer Immunotherapy Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Cancer Immunotherapy Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Cancer Immunotherapy Drug Sales by Region (2021-2026) & (k units) Table 43. Global Cancer Immunotherapy Drug Sales Market Share in Volume by Region (2021-2026) Table 44. Global Cancer Immunotherapy Drug Sales by Region (2021-2026) & (US$ Million) Table 45. Global Cancer Immunotherapy Drug Sales Market Share in Value by Region (2021-2026) Table 46. Global Cancer Immunotherapy Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 47. Global Cancer Immunotherapy Drug Sales by Region (2027-2032) & (k units) Table 48. Global Cancer Immunotherapy Drug Sales Market Share in Volume by Region (2027-2032) Table 49. Global Cancer Immunotherapy Drug Sales by Region (2027-2032) & (US$ Million) Table 50. Global Cancer Immunotherapy Drug Sales Market Share in Value by Region (2027-2032) Table 51. Global Cancer Immunotherapy Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 52. Global Cancer Immunotherapy Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Cancer Immunotherapy Drug Sales by Application (2021-2026) & (k units) Table 54. Global Cancer Immunotherapy Drug Sales Market Share in Volume by Application (2021-2026) Table 55. Global Cancer Immunotherapy Drug Sales by Application (2021-2026) & (US$ Million) Table 56. Global Cancer Immunotherapy Drug Sales Market Share in Value by Application (2021-2026) Table 57. Global Cancer Immunotherapy Drug Price by Application (2021-2026) & (US$/unit) Table 58. Global Cancer Immunotherapy Drug Sales by Application (2027-2032) & (k units) Table 59. Global Cancer Immunotherapy Drug Sales Market Share in Volume by Application (2027-2032) Table 60. Global Cancer Immunotherapy Drug Sales by Application (2027-2032) & (US$ Million) Table 61. Global Cancer Immunotherapy Drug Sales Market Share in Value by Application (2027-2032) Table 62. Global Cancer Immunotherapy Drug Price by Application (2027-2032) & (US$/unit) Table 63. North America Cancer Immunotherapy Drug Sales by Application (2021-2026) & (k units) Table 64. North America Cancer Immunotherapy Drug Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Cancer Immunotherapy Drug Sales by Application (2021-2026) & (k units) Table 66. Europe Cancer Immunotherapy Drug Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Cancer Immunotherapy Drug Sales by Application (2021-2026) & (k units) Table 68. Asia-Pacific Cancer Immunotherapy Drug Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Cancer Immunotherapy Drug Sales by Application (2021-2026) & (k units) Table 70. Latin America Cancer Immunotherapy Drug Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Cancer Immunotherapy Drug Sales by Application (2021-2026) & (k units) Table 72. Middle East and Africa Cancer Immunotherapy Drug Sales by Application (2021-2026) & (US$ Million) Table 73. Novartis AG Company Information Table 74. Novartis AG Business Overview Table 75. Novartis AG Cancer Immunotherapy Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Novartis AG Cancer Immunotherapy Drug Product Portfolio Table 77. Novartis AG Recent Development Table 78. Merck & Co., Inc. Company Information Table 79. Merck & Co., Inc. Business Overview Table 80. Merck & Co., Inc. Cancer Immunotherapy Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Merck & Co., Inc. Cancer Immunotherapy Drug Product Portfolio Table 82. Merck & Co., Inc. Recent Development Table 83. Jiangsu Hengrui Medicine Corporation Company Information Table 84. Jiangsu Hengrui Medicine Corporation Business Overview Table 85. Jiangsu Hengrui Medicine Corporation Cancer Immunotherapy Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Jiangsu Hengrui Medicine Corporation Cancer Immunotherapy Drug Product Portfolio Table 87. Jiangsu Hengrui Medicine Corporation Recent Development Table 88. Pfizer, Inc. Company Information Table 89. Pfizer, Inc. Business Overview Table 90. Pfizer, Inc. Cancer Immunotherapy Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Pfizer, Inc. Cancer Immunotherapy Drug Product Portfolio Table 92. Pfizer, Inc. Recent Development Table 93. Bristol-Myers Squibb Company Company Information Table 94. Bristol-Myers Squibb Company Business Overview Table 95. Bristol-Myers Squibb Company Cancer Immunotherapy Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Bristol-Myers Squibb Company Cancer Immunotherapy Drug Product Portfolio Table 97. Bristol-Myers Squibb Company Recent Development Table 98. AstraZeneca plc Company Information Table 99. AstraZeneca plc Business Overview Table 100. AstraZeneca plc Cancer Immunotherapy Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. AstraZeneca plc Cancer Immunotherapy Drug Product Portfolio Table 102. AstraZeneca plc Recent Development Table 103. Roche Holding AG Company Information Table 104. Roche Holding AG Business Overview Table 105. Roche Holding AG Cancer Immunotherapy Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Roche Holding AG Cancer Immunotherapy Drug Product Portfolio Table 107. Roche Holding AG Recent Development Table 108. Medimmune, LLC Company Information Table 109. Medimmune, LLC Business Overview Table 110. Medimmune, LLC Cancer Immunotherapy Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. Medimmune, LLC Cancer Immunotherapy Drug Product Portfolio Table 112. Medimmune, LLC Recent Development Table 113. Juno Pharmaceuticals Pty Ltd. Company Information Table 114. Juno Pharmaceuticals Pty Ltd. Business Overview Table 115. Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 116. Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Product Portfolio Table 117. Juno Pharmaceuticals Pty Ltd. Recent Development Table 118. Incyte Corporation Company Information Table 119. Incyte Corporation Business Overview Table 120. Incyte Corporation Cancer Immunotherapy Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 121. Incyte Corporation Cancer Immunotherapy Drug Product Portfolio Table 122. Incyte Corporation Recent Development Table 123. Gilead Sciences, Inc. (Kite Pharma) Company Information Table 124. Gilead Sciences, Inc. (Kite Pharma) Business Overview Table 125. Gilead Sciences, Inc. (Kite Pharma) Cancer Immunotherapy Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 126. Gilead Sciences, Inc. (Kite Pharma) Cancer Immunotherapy Drug Product Portfolio Table 127. Gilead Sciences, Inc. (Kite Pharma) Recent Development Table 128. Celgene Corporation Company Information Table 129. Celgene Corporation Business Overview Table 130. Celgene Corporation Cancer Immunotherapy Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 131. Celgene Corporation Cancer Immunotherapy Drug Product Portfolio Table 132. Celgene Corporation Recent Development Table 133. bluebird bio, Inc. Company Information Table 134. bluebird bio, Inc. Business Overview Table 135. bluebird bio, Inc. Cancer Immunotherapy Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 136. bluebird bio, Inc. Cancer Immunotherapy Drug Product Portfolio Table 137. bluebird bio, Inc. Recent Development Table 138. BeiGene Company Information Table 139. BeiGene Business Overview Table 140. BeiGene Cancer Immunotherapy Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 141. BeiGene Cancer Immunotherapy Drug Product Portfolio Table 142. BeiGene Recent Development Table 143. Autolus Therapeutics plc Company Information Table 144. Autolus Therapeutics plc Business Overview Table 145. Autolus Therapeutics plc Cancer Immunotherapy Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 146. Autolus Therapeutics plc Cancer Immunotherapy Drug Product Portfolio Table 147. Autolus Therapeutics plc Recent Development Table 148. North America Cancer Immunotherapy Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 149. North America Cancer Immunotherapy Drug Sales by Country (2021-2026) & (k units) Table 150. North America Cancer Immunotherapy Drug Sales Market Share by Country (2021-2026) Table 151. North America Cancer Immunotherapy Drug Sales Forecast by Country (2027-2032) & (k units) Table 152. North America Cancer Immunotherapy Drug Sales Market Share Forecast by Country (2027-2032) Table 153. North America Cancer Immunotherapy Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. North America Cancer Immunotherapy Drug Market Size by Country (2021-2026) & (US$ Million) Table 155. North America Cancer Immunotherapy Drug Market Share by Country (2021-2026) Table 156. North America Cancer Immunotherapy Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. North America Cancer Immunotherapy Drug Market Share Forecast by Country (2027-2032) Table 158. Europe Cancer Immunotherapy Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 159. Europe Cancer Immunotherapy Drug Sales by Country (2021-2026) & (k units) Table 160. Europe Cancer Immunotherapy Drug Sales Market Share by Country (2021-2026) Table 161. Europe Cancer Immunotherapy Drug Sales Forecast by Country (2027-2032) & (k units) Table 162. Europe Cancer Immunotherapy Drug Sales Market Share Forecast by Country (2027-2032) Table 163. Europe Cancer Immunotherapy Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 164. Europe Cancer Immunotherapy Drug Market Size by Country (2021-2026) & (US$ Million) Table 165. Europe Cancer Immunotherapy Drug Market Share by Country (2021-2026) Table 166. Europe Cancer Immunotherapy Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 167. Europe Cancer Immunotherapy Drug Market Share Forecast by Country (2027-2032) Table 168. Asia-Pacific Cancer Immunotherapy Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 169. Asia-Pacific Cancer Immunotherapy Drug Sales by Country (2021-2026) & (k units) Table 170. Asia-Pacific Cancer Immunotherapy Drug Sales Market Share by Country (2021-2026) Table 171. Asia-Pacific Cancer Immunotherapy Drug Sales Forecast by Country (2027-2032) & (k units) Table 172. Asia-Pacific Cancer Immunotherapy Drug Sales Market Share Forecast by Country (2027-2032) Table 173. Asia-Pacific Cancer Immunotherapy Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 174. Asia-Pacific Cancer Immunotherapy Drug Market Size by Country (2021-2026) & (US$ Million) Table 175. Asia-Pacific Cancer Immunotherapy Drug Market Share by Country (2021-2026) Table 176. Asia-Pacific Cancer Immunotherapy Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 177. Asia-Pacific Cancer Immunotherapy Drug Market Share Forecast by Country (2027-2032) Table 178. Latin America Cancer Immunotherapy Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 179. Latin America Cancer Immunotherapy Drug Sales by Country (2021-2026) & (k units) Table 180. Latin America Cancer Immunotherapy Drug Sales Market Share by Country (2021-2026) Table 181. Latin America Cancer Immunotherapy Drug Sales Forecast by Country (2027-2032) & (k units) Table 182. Latin America Cancer Immunotherapy Drug Sales Market Share Forecast by Country (2027-2032) Table 183. Latin America Cancer Immunotherapy Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 184. Latin America Cancer Immunotherapy Drug Market Size by Country (2021-2026) & (US$ Million) Table 185. Latin America Cancer Immunotherapy Drug Market Share by Country (2021-2026) Table 186. Latin America Cancer Immunotherapy Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 187. Latin America Cancer Immunotherapy Drug Market Share Forecast by Country (2027-2032) Table 188. Middle East and Africa Cancer Immunotherapy Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 189. Middle East and Africa Cancer Immunotherapy Drug Sales by Country (2021-2026) & (k units) Table 190. Middle East and Africa Cancer Immunotherapy Drug Sales Market Share by Country (2021-2026) Table 191. Middle East and Africa Cancer Immunotherapy Drug Sales Forecast by Country (2027-2032) & (k units) Table 192. Middle East and Africa Cancer Immunotherapy Drug Sales Market Share Forecast by Country (2027-2032) Table 193. Middle East and Africa Cancer Immunotherapy Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 194. Middle East and Africa Cancer Immunotherapy Drug Market Size by Country (2021-2026) & (US$ Million) Table 195. Middle East and Africa Cancer Immunotherapy Drug Market Share by Country (2021-2026) Table 196. Middle East and Africa Cancer Immunotherapy Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 197. Middle East and Africa Cancer Immunotherapy Drug Market Share Forecast by Country (2027-2032) Table 198. Key Raw Materials Table 199. Raw Materials Key Suppliers Table 200. Cancer Immunotherapy Drug Distributors List Table 201. Cancer Immunotherapy Drug Customers List Table 202. Research Programs/Design for This Report Table 203. Authors List of This Report Table 204. Secondary Sources Table 205. Primary Sources List of Figures Figure 1. Cancer Immunotherapy Drug Image Figure 2. Global Cancer Immunotherapy Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cancer Immunotherapy Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Cancer Immunotherapy Drug Sales (2021-2032) & (k units) Figure 5. T-Cell Stimulant Image Figure 6. Global T-Cell Stimulant Sales YoY Growth (2021-2032) & (k units) Figure 7. PDL-1 Inhibitor Image Figure 8. Global PDL-1 Inhibitor Sales YoY Growth (2021-2032) & (k units) Figure 9. PD-1 Inhibitor Image Figure 10. Global PD-1 Inhibitor Sales YoY Growth (2021-2032) & (k units) Figure 11. CTLA Antibody Image Figure 12. Global CTLA Antibody Sales YoY Growth (2021-2032) & (k units) Figure 13. Global Cancer Immunotherapy Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Cancer Immunotherapy Drug Market Share by Type 2025 VS 2032 Figure 15. North America Cancer Immunotherapy Drug Sales Market Share in Volume by Type in 2025 Figure 16. North America Cancer Immunotherapy Drug Sales Market Share in Value by Type in 2025 Figure 17. Europe Cancer Immunotherapy Drug Sales Market Share in Volume by Type in 2025 Figure 18. Europe Cancer Immunotherapy Drug Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Cancer Immunotherapy Drug Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Cancer Immunotherapy Drug Sales Market Share in Value by Type in 2025 Figure 21. Latin America Cancer Immunotherapy Drug Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Cancer Immunotherapy Drug Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Cancer Immunotherapy Drug Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Cancer Immunotherapy Drug Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Cancer Immunotherapy Drug Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Hospital Image Figure 28. Global Hospital Sales YoY Growth (2021-2032) & (k units) Figure 29. Clinic Image Figure 30. Global Clinic Sales YoY Growth (2021-2032) & (k units) Figure 31. Others Image Figure 32. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 33. Global Cancer Immunotherapy Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Cancer Immunotherapy Drug Market Share by Application 2025 VS 2032 Figure 35. North America Cancer Immunotherapy Drug Sales Market Share in Volume by Application in 2025 Figure 36. North America Cancer Immunotherapy Drug Sales Market Share in Value by Application in 2025 Figure 37. Europe Cancer Immunotherapy Drug Sales Market Share in Volume by Application in 2025 Figure 38. Europe Cancer Immunotherapy Drug Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Cancer Immunotherapy Drug Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Cancer Immunotherapy Drug Sales Market Share in Value by Application in 2025 Figure 41. Latin America Cancer Immunotherapy Drug Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Cancer Immunotherapy Drug Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Cancer Immunotherapy Drug Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Cancer Immunotherapy Drug Sales Market Share in Value by Application in 2025 Figure 45. North America Cancer Immunotherapy Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 46. North America Cancer Immunotherapy Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Cancer Immunotherapy Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Cancer Immunotherapy Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Cancer Immunotherapy Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 50. Europe Cancer Immunotherapy Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Cancer Immunotherapy Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Cancer Immunotherapy Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Cancer Immunotherapy Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 54. Asia-Pacific Cancer Immunotherapy Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Cancer Immunotherapy Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Cancer Immunotherapy Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Cancer Immunotherapy Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 58. Latin America Cancer Immunotherapy Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Cancer Immunotherapy Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Cancer Immunotherapy Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Cancer Immunotherapy Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 62. Middle East and Africa Cancer Immunotherapy Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Cancer Immunotherapy Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Cancer Immunotherapy Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Cancer Immunotherapy Drug Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Cancer Immunotherapy Drug Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • T-Cell Stimulant
  • PDL-1 Inhibitor
  • PD-1 Inhibitor
  • CTLA Antibody
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Novartis AG
  • Merck & Co., Inc.
  • Jiangsu Hengrui Medicine Corporation
  • Pfizer, Inc.
  • Bristol-Myers Squibb Company
  • AstraZeneca plc
  • Roche Holding AG
  • Medimmune, LLC
  • Juno Pharmaceuticals Pty Ltd.
  • Incyte Corporation
  • Gilead Sciences, Inc. (Kite Pharma)
  • Celgene Corporation
  • bluebird bio, Inc.
  • BeiGene
  • Autolus Therapeutics plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Cancer Immunotherapy Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Cancer Immunotherapy Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Cancer Immunotherapy Drug Market by Type
  6. 1.3.1 T-Cell Stimulant
  7. 1.3.2 PDL-1 Inhibitor
  8. 1.3.3 PD-1 Inhibitor
  9. 1.3.4 CTLA Antibody
  10. 1.4 Global Cancer Immunotherapy Drug Market Size by Type
  11. 1.4.1 Global Cancer Immunotherapy Drug Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Cancer Immunotherapy Drug Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Cancer Immunotherapy Drug Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Cancer Immunotherapy Drug Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Cancer Immunotherapy Drug Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Cancer Immunotherapy Drug Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Cancer Immunotherapy Drug Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Cancer Immunotherapy Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Cancer Immunotherapy Drug Industry Trends
  2. 2.2 Cancer Immunotherapy Drug Industry Drivers
  3. 2.3 Cancer Immunotherapy Drug Industry Opportunities and Challenges
  4. 2.4 Cancer Immunotherapy Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Cancer Immunotherapy Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Cancer Immunotherapy Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Cancer Immunotherapy Drug Price (2021-2026)
  4. 3.4 Global Cancer Immunotherapy Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Cancer Immunotherapy Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Cancer Immunotherapy Drug Company, Product Type & Application
  7. 3.7 Global Cancer Immunotherapy Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Cancer Immunotherapy Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Cancer Immunotherapy Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Cancer Immunotherapy Drug Tier 1, Tier 2, and Tier 3
4 Cancer Immunotherapy Drug Regional Status and Outlook
  1. 4.1 Global Cancer Immunotherapy Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Cancer Immunotherapy Drug Historic Market Size by Region
  3. 4.2.1 Global Cancer Immunotherapy Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Cancer Immunotherapy Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Cancer Immunotherapy Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Cancer Immunotherapy Drug Forecasted Market Size by Region
  7. 4.3.1 Global Cancer Immunotherapy Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Cancer Immunotherapy Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Cancer Immunotherapy Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Cancer Immunotherapy Drug by Application
  1. 5.1 Cancer Immunotherapy Drug Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Cancer Immunotherapy Drug Market Size by Application
  6. 5.2.1 Global Cancer Immunotherapy Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Cancer Immunotherapy Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Cancer Immunotherapy Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Cancer Immunotherapy Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Cancer Immunotherapy Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Cancer Immunotherapy Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Cancer Immunotherapy Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Cancer Immunotherapy Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Novartis AG
  2. 6.1.1 Novartis AG Company Information
  3. 6.1.2 Novartis AG Business Overview
  4. 6.1.3 Novartis AG Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Novartis AG Cancer Immunotherapy Drug Product Portfolio
  6. 6.1.5 Novartis AG Recent Developments
  7. 6.2 Merck & Co., Inc.
  8. 6.2.1 Merck & Co., Inc. Company Information
  9. 6.2.2 Merck & Co., Inc. Business Overview
  10. 6.2.3 Merck & Co., Inc. Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Merck & Co., Inc. Cancer Immunotherapy Drug Product Portfolio
  12. 6.2.5 Merck & Co., Inc. Recent Developments
  13. 6.3 Jiangsu Hengrui Medicine Corporation
  14. 6.3.1 Jiangsu Hengrui Medicine Corporation Company Information
  15. 6.3.2 Jiangsu Hengrui Medicine Corporation Business Overview
  16. 6.3.3 Jiangsu Hengrui Medicine Corporation Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Jiangsu Hengrui Medicine Corporation Cancer Immunotherapy Drug Product Portfolio
  18. 6.3.5 Jiangsu Hengrui Medicine Corporation Recent Developments
  19. 6.4 Pfizer, Inc.
  20. 6.4.1 Pfizer, Inc. Company Information
  21. 6.4.2 Pfizer, Inc. Business Overview
  22. 6.4.3 Pfizer, Inc. Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Pfizer, Inc. Cancer Immunotherapy Drug Product Portfolio
  24. 6.4.5 Pfizer, Inc. Recent Developments
  25. 6.5 Bristol-Myers Squibb Company
  26. 6.5.1 Bristol-Myers Squibb Company Company Information
  27. 6.5.2 Bristol-Myers Squibb Company Business Overview
  28. 6.5.3 Bristol-Myers Squibb Company Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Bristol-Myers Squibb Company Cancer Immunotherapy Drug Product Portfolio
  30. 6.5.5 Bristol-Myers Squibb Company Recent Developments
  31. 6.6 AstraZeneca plc
  32. 6.6.1 AstraZeneca plc Company Information
  33. 6.6.2 AstraZeneca plc Business Overview
  34. 6.6.3 AstraZeneca plc Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 AstraZeneca plc Cancer Immunotherapy Drug Product Portfolio
  36. 6.6.5 AstraZeneca plc Recent Developments
  37. 6.7 Roche Holding AG
  38. 6.7.1 Roche Holding AG Company Information
  39. 6.7.2 Roche Holding AG Business Overview
  40. 6.7.3 Roche Holding AG Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Roche Holding AG Cancer Immunotherapy Drug Product Portfolio
  42. 6.7.5 Roche Holding AG Recent Developments
  43. 6.8 Medimmune, LLC
  44. 6.8.1 Medimmune, LLC Company Information
  45. 6.8.2 Medimmune, LLC Business Overview
  46. 6.8.3 Medimmune, LLC Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Medimmune, LLC Cancer Immunotherapy Drug Product Portfolio
  48. 6.8.5 Medimmune, LLC Recent Developments
  49. 6.9 Juno Pharmaceuticals Pty Ltd.
  50. 6.9.1 Juno Pharmaceuticals Pty Ltd. Company Information
  51. 6.9.2 Juno Pharmaceuticals Pty Ltd. Business Overview
  52. 6.9.3 Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Product Portfolio
  54. 6.9.5 Juno Pharmaceuticals Pty Ltd. Recent Developments
  55. 6.10 Incyte Corporation
  56. 6.10.1 Incyte Corporation Company Information
  57. 6.10.2 Incyte Corporation Business Overview
  58. 6.10.3 Incyte Corporation Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Incyte Corporation Cancer Immunotherapy Drug Product Portfolio
  60. 6.10.5 Incyte Corporation Recent Developments
  61. 6.11 Gilead Sciences, Inc. (Kite Pharma)
  62. 6.11.1 Gilead Sciences, Inc. (Kite Pharma) Company Information
  63. 6.11.2 Gilead Sciences, Inc. (Kite Pharma) Business Overview
  64. 6.11.3 Gilead Sciences, Inc. (Kite Pharma) Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Gilead Sciences, Inc. (Kite Pharma) Cancer Immunotherapy Drug Product Portfolio
  66. 6.11.5 Gilead Sciences, Inc. (Kite Pharma) Recent Developments
  67. 6.12 Celgene Corporation
  68. 6.12.1 Celgene Corporation Company Information
  69. 6.12.2 Celgene Corporation Business Overview
  70. 6.12.3 Celgene Corporation Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Celgene Corporation Cancer Immunotherapy Drug Product Portfolio
  72. 6.12.5 Celgene Corporation Recent Developments
  73. 6.13 bluebird bio, Inc.
  74. 6.13.1 bluebird bio, Inc. Company Information
  75. 6.13.2 bluebird bio, Inc. Business Overview
  76. 6.13.3 bluebird bio, Inc. Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 bluebird bio, Inc. Cancer Immunotherapy Drug Product Portfolio
  78. 6.13.5 bluebird bio, Inc. Recent Developments
  79. 6.14 BeiGene
  80. 6.14.1 BeiGene Company Information
  81. 6.14.2 BeiGene Business Overview
  82. 6.14.3 BeiGene Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 BeiGene Cancer Immunotherapy Drug Product Portfolio
  84. 6.14.5 BeiGene Recent Developments
  85. 6.15 Autolus Therapeutics plc
  86. 6.15.1 Autolus Therapeutics plc Company Information
  87. 6.15.2 Autolus Therapeutics plc Business Overview
  88. 6.15.3 Autolus Therapeutics plc Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Autolus Therapeutics plc Cancer Immunotherapy Drug Product Portfolio
  90. 6.15.5 Autolus Therapeutics plc Recent Developments
7 North America by Country
  1. 7.1 North America Cancer Immunotherapy Drug Sales by Country
  2. 7.1.1 North America Cancer Immunotherapy Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Cancer Immunotherapy Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Cancer Immunotherapy Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Cancer Immunotherapy Drug Market Size by Country
  6. 7.2.1 North America Cancer Immunotherapy Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Cancer Immunotherapy Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Cancer Immunotherapy Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Cancer Immunotherapy Drug Sales by Country
  2. 8.1.1 Europe Cancer Immunotherapy Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Cancer Immunotherapy Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Cancer Immunotherapy Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Cancer Immunotherapy Drug Market Size by Country
  6. 8.2.1 Europe Cancer Immunotherapy Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Cancer Immunotherapy Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Cancer Immunotherapy Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Cancer Immunotherapy Drug Sales by Country
  2. 9.1.1 Asia-Pacific Cancer Immunotherapy Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Cancer Immunotherapy Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Cancer Immunotherapy Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Cancer Immunotherapy Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Cancer Immunotherapy Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Cancer Immunotherapy Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Cancer Immunotherapy Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Cancer Immunotherapy Drug Sales by Country
  2. 10.1.1 South America Cancer Immunotherapy Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Cancer Immunotherapy Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Cancer Immunotherapy Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Cancer Immunotherapy Drug Market Size by Country
  6. 10.2.1 South America Cancer Immunotherapy Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Cancer Immunotherapy Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Cancer Immunotherapy Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Cancer Immunotherapy Drug Sales by Country
  2. 11.1.1 Middle East and Africa Cancer Immunotherapy Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Cancer Immunotherapy Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Cancer Immunotherapy Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Cancer Immunotherapy Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Cancer Immunotherapy Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Cancer Immunotherapy Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Cancer Immunotherapy Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Cancer Immunotherapy Drug Value Chain Analysis
  2. 12.1.1 Cancer Immunotherapy Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Cancer Immunotherapy Drug Production Mode & Process
  7. 12.2 Cancer Immunotherapy Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Cancer Immunotherapy Drug Distributors
  10. 12.2.3 Cancer Immunotherapy Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst